PLEXIFORM NEUROFIBROMA
Clinical trials for PLEXIFORM NEUROFIBROMA explained in plain language.
Never miss a new study
Get alerted when new PLEXIFORM NEUROFIBROMA trials appear
Sign up with your email to follow new studies for PLEXIFORM NEUROFIBROMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Hard-to-Treat brain tumors: targeted drug shows promise
Disease control OngoingThis study tests a daily oral drug called trametinib in children and young adults (ages 1 month to 25 years) with low-grade glioma or plexiform neurofibroma that has not responded to other treatments. The drug targets a specific growth pathway (MAPK/ERK) that is overactive in the…
Matched conditions: PLEXIFORM NEUROFIBROMA
Phase: PHASE2 • Sponsor: St. Justine's Hospital • Aim: Disease control
Last updated May 26, 2026 05:30 UTC
-
New drug shrinks untouchable tumors in NF1 patients
Disease control OngoingThis study tests a daily pill called mirdametinib in 114 adults and children with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be surgically removed and are causing serious problems. The goal is to see if the drug can shrink these tumors by at least 20%. Parti…
Matched conditions: PLEXIFORM NEUROFIBROMA
Phase: PHASE2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated May 26, 2026 05:23 UTC
-
10-Year study aims to unlock mysteries of rare genetic disorder
Knowledge-focused OngoingThis study follows 259 children and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers track tumors, quality of life, and other health changes to better understand how the disease progresses. The goal is to gather information that could help design better …
Matched conditions: PLEXIFORM NEUROFIBROMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 05:22 UTC